Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.
Our success as a BioPharma leader has been fueled by our pioneering approach to bolster our early- and mid-stage research and pipeline through a series of acquisitions, collaborations, alliances and agreements. They have helped balance our portfolio and build clusters of expertise in key therapeutic areas where there is great unmet medical need. We acquired skilled people, great science, potential products and in some areas, marketed products. And we’ve positioned ourselves as a strong partner in biotech circles by demonstrating our ability to nurture innovation, assets and talent.